## Prescriber Criteria Form

## Skyrizi 2025 PA Fax 3048-A v3 010125.docx Skyrizi (risankizumab-rzaa) Coverage Determination

This fax machine is located in a secure location as required by HIPAA regulations.

Complete/review information, sign and date. Fax signed forms to CVS Caremark at **1-855-633-7673**. Please contact CVS Caremark at **1-866-785-5714** with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Skyrizi (risankizumab-rzaa).

Drug Name:

Skyrizi (risankizumab-rzaa)				
D. (1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1				
Patient Name:				
Patient ID:				
Patient DOB:	Patient Phone:	Patient Phone:		
Prescriber Name:	·			
Prescriber Address:				
City:	State:	Zip:		
Prescriber Phone:	Prescriber Fax:	<u>,</u>		
Diagnosis:	ICD Code(s):			

Please	e circle the appropriate answer for each question.		
1	Has the patient previously received the requested drug for one of the following conditions:  A) plaque psoriasis, B) psoriatic arthritis, C) Crohn's disease, D) ulcerative colitis?  [If yes, then no further questions.]	Yes	No
2	Does the patient have a diagnosis of moderate to severe plaque psoriasis? [If no, then skip to question 5.]	Yes	No
3	Does the patient meet one of the following criteria: A) at least 3 percent of body surface area (BSA) is affected by plaque psoriasis at the time of diagnosis, B) crucial body areas (e.g., feet, hands, face, neck, groin, intertriginous areas) are affected by plaque psoriasis at the time of diagnosis?  [If no, then no further questions.]	Yes	No
4	Does the patient meet any of the following criteria: A) patient has experienced an inadequate treatment response or intolerance to either phototherapy (e.g., ultraviolet B [UVB], psoralen plus ultraviolet A [PUVA]) or pharmacologic treatment with methotrexate, cyclosporine, or acitretin, B) pharmacologic treatment with methotrexate, cyclosporine, or acitretin is contraindicated, C) patient has severe psoriasis that warrants a biologic as first-line therapy (i.e. at least 10 percent of the body surface area [BSA] or crucial body areas [e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas] are affected)? [No further questions.]	Yes	No

Prescri	ber (or Authorized) Signature: Date:		
, ,	ing this form, I attest that the information provided is accurate and true as of this date and the entation supporting this information is available for review if requested by the health plan.	nat the	
Comme	ents:		
7	Does the patient have a diagnosis of moderately to severely active ulcerative colitis?	Yes	No
6	Does the patient have a diagnosis of moderately to severely active Crohn's disease? [If yes, then no further questions.]	Yes	No
5	Does the patient have a diagnosis of active psoriatic arthritis? [If yes, then no further questions.]	Yes	No